Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2005
11/23/2005CN1700928A Methods and preparations for curing critically ill patients
11/23/2005CN1700894A Methods of treating dry eye disease with lantibiotics
11/23/2005CN1699410A Apolipoprotein A-1 agonists and their use to treat dyslipidemic disorders
11/23/2005CN1698894A Tumor necrosis factor antagonists and their use in endometriosis
11/23/2005CN1698891A Medicine of human lysozyme, its production method and application
11/23/2005CN1698890A Powder of human lysozyme, its production method and application
11/23/2005CN1698889A Insulin dripping pills and its preparation process
11/23/2005CN1698888A Oral cavity plastering sheet of interferon and its preparation method
11/23/2005CN1698887A Vaginal effervescence tablet of interferon and its preparation method
11/23/2005CN1698886A Application of interleukin-1 in medicine preparation process for treating glaucoma
11/23/2005CN1698885A Application of liver cell growth factor in preventing and treating tissue accretion
11/23/2005CN1698884A Application of nerve growth factor in preparation of medicine for treating lasting vegetative state
11/23/2005CN1698883A Application of nerve growth factor in preparation of medicine for effective reducing body weight
11/23/2005CN1698882A Application of nerve growth factor in preparation of medicine for treating depression
11/23/2005CN1698881A Long lasting fusion peptide inhibitors of viral infection
11/23/2005CN1698880A Application of cyclophilin compound in preparation of medicine for preventing and treating bronchial asthma
11/23/2005CN1698879A Product having sobering up and liver protecting functions and its preparation method and usage
11/23/2005CN1228446C Conotoxin MVII A and Trx fusion protein and its expression and application
11/23/2005CN1228346C Short peptide and its derivative and medicine with them as active component and use thereof
11/23/2005CN1228084C Method of using Zot or zonulin to inhibit lymphocyte proliferation in antigen-specific manner
11/23/2005CN1228083C Skin wound healing promoters
11/23/2005CN1228082C Method for preparing pharmaceutics of hydrolysate of brain protein
11/22/2005US6967239 obtaining a starting factor VIII solution comprising factor VIII-von Willebrand factor complexes; and filtering in presence of calcium chloride ions through hydrophilic virus filter having a mean pore size of 13 to 17 nm
11/22/2005US6967238 Compounds and methods for modulating cell adhesion
11/22/2005US6967237 For use in stimulating growth hormone secretion
11/22/2005US6967192 Seventeen amino acid peptide (Peptide P) for treating ischemia and reperfusion injury
11/22/2005US6967191 System capable of increasing retinal and neural glucose oxidation by enhancing pyruvate dehydrogenase activity and therefore treats retinopathy and central nervous system disorders in both diabetic and nondiabetic patients. The
11/22/2005US6967100 Propagating islet of langerhans cells; obtain cells, culture in presence of bone morphogenic protein or modulator, monitor proliferation of cells
11/22/2005US6967097 Nucleotide sequences coding enzymatic polypeptide for use in the treatment of viral diseases
11/22/2005US6967094 Peptide for use in treatment of cancer, parkinson's and metabolic disorders
11/22/2005US6967093 Glycosyl sulfotransferase-3
11/22/2005US6967091 Lowering circulating free fatty acid levels in an individual by administering to polypeptide and carrier
11/22/2005US6967090 Nucleic acid and protein sequences of bovine epidermal growth factor
11/22/2005US6967089 Delivery system for porcine somatotropin
11/22/2005US6967077 Methods and compositions for regulating T cell subsets by modulating transcription factor activity
11/22/2005US6967029 Method for increasing hematopoietic progenitor cells by stem cell factor
11/22/2005US6967021 Overcoming persistent epithelial defects; preventing recurrent erosion
11/22/2005US6967020 Oxygen carrier system, artificial oxygen carrier, and reducing agent
11/22/2005US6967018 Adiponectin gene therapy
11/22/2005US6966186 Non-catalytic combustor for reducing NOx emissions
11/22/2005CA2262469C Uses for wnt polypeptides
11/22/2005CA2251558C Highly purified factor viii complex
11/22/2005CA2244767C Process for the production of powdered pulmonary surfactant preparations
11/22/2005CA2171531C Multiple branch peptide constructions for use against hiv
11/22/2005CA2154164C Excipient stabilization of polypeptides treated with organic solvents
11/22/2005CA2153348C Enteral diet and method for providing nutrition to a diabetic
11/17/2005WO2005108996A1 Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 10 (dpp10)
11/17/2005WO2005108576A1 Novel crustacean proline-rich peptides
11/17/2005WO2005108574A1 Gm1 PROMOTER AND USE THEREOF
11/17/2005WO2005108563A2 Peptidoglycan-hydrolyzing protein encoded by bacteriophage n4
11/17/2005WO2005108562A2 Synthetic fluorouridine-activating enzyme for cancer therapy
11/17/2005WO2005108432A2 Cd80 (b7-1) binding peptides and uses thereof
11/17/2005WO2005108423A1 Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
11/17/2005WO2005108422A2 Ammonium/ammonia transporter
11/17/2005WO2005108420A1 Cancer associated antigens
11/17/2005WO2005108416A2 Myosin light chain kinase inhibitors and their use
11/17/2005WO2005108354A1 Use of biphenyl-derived thiamides as calpain inhibitors
11/17/2005WO2005107802A2 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
11/17/2005WO2005107795A1 Use of factor viia for the treatment of burn traumas
11/17/2005WO2005107794A1 An agent comprising fgf2 as an effective ingredient for treatment or prevention of asthma and chronic obstructive pulmonary disease
11/17/2005WO2005107793A2 Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
11/17/2005WO2005107792A2 Compositions and methods for treatment of protein misfolding diseases
11/17/2005WO2005107791A1 Medicament for the treatment of fungal infections, particularly aspergillosis
11/17/2005WO2005107790A1 Hybrid recombinases for genome manipulation
11/17/2005WO2005107789A1 Use of delta pkc peptides for modulation of reactive oxigen species
11/17/2005WO2005107788A1 Inhibition of allergic contact dermatitis by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester
11/17/2005WO2005107787A1 Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
11/17/2005WO2005107786A1 Therapeutic enzyme formulations and uses thereof
11/17/2005WO2005107785A2 Human complement c3 derivates with cobra venom factor-like function
11/17/2005WO2005107784A1 Remedy for thrombopenia
11/17/2005WO2005107783A1 Food containing extract from bark of pine
11/17/2005WO2005107778A1 Body fat reducing preparation
11/17/2005WO2005107776A1 METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
11/17/2005WO2005107767A2 Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
11/17/2005WO2005107745A1 An inhibitor of hepatitis c
11/17/2005WO2005107730A2 Cysteamines for treating complications of hypercholesterolemia and diabetes
11/17/2005WO2005107357A2 Analgesic peptides derived from the venom of crotalus durissus terrificuss snakes
11/17/2005WO2005089080A3 Method and kit for screening, pharmaceutical compositions and method for treatment of autoimmune disorders
11/17/2005WO2005077423A3 Adept or gdept producing acetaldehyde
11/17/2005WO2005060960A3 Use of histamine to treat bone disease
11/17/2005WO2005057218A3 Methods of identifying modulators of apoptosis from parasites and uses thereof
11/17/2005WO2005049648A3 Chimeric or fusion constructs of insulin-like growth factor binding proteins as chemotherapeutic agents
11/17/2005WO2005049063A3 Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
11/17/2005WO2005046714A3 Cytokine antagonist molecules
11/17/2005WO2005041870A3 Composition and method for the treatment of eye disease
11/17/2005WO2005039643A3 In vivo gene therapy of parkinson's disease
11/17/2005WO2005025595B1 Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
11/17/2005WO2005023311A3 Novel targets for the treatment of retina diseases
11/17/2005WO2005020972A3 Combination therapy for the treatment of ocular neovascular disorders
11/17/2005WO2005016227A3 Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
11/17/2005WO2005000222A3 Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
11/17/2005WO2004082602A3 Carboxamide spirohydantoin cgrp receptor antagonists
11/17/2005WO2004078140A3 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
11/17/2005WO2004063331A9 SiRNA MEDIATED POST-TRANSRIPTIONAL GENE SILENCING OF GENES INVOLVED IN ALOPECIA
11/17/2005WO2004048534A3 Modulation of cytokine-inducible kinase expression
11/17/2005WO2004005318A3 Peptides comprising aromatic d-amino acids and methods of use
11/17/2005WO2003084483A3 Methods for modulating angiogenesis via vegf
11/17/2005WO2003068941A3 Modulation of immune response by non-peptide binding stress response polypeptides
11/17/2005WO2003042399A8 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
11/17/2005WO2001065911A9 Improved poloxamer and poloxamine compositions for nucleic acid delivery
1 ... 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 ... 3163